ABIONYX Pharma (LSE:0RAG) - Stock Price, News & Analysis

0RAG Stock Overview

A biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. More details

0RAG fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 40.7% per year

Risk Analysis

Earnings are forecast to decline by an average of 23.4% per year for the next 3 years

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (€42M)

+ 1 more risk

ABIONYX Pharma SA Competitors

Arecor Therapeutics

AIM:AREC

UK£28.3m

Tissue Regenix Group

AIM:TRX

UK£40.6m

Avacta Group

AIM:AVCT

UK£179.3m

ProBiotix Health

OFEX:PBX

UK£10.3m

Price History & Performance

Summary of all time highs, changes and price drops for ABIONYX Pharma
Historical stock prices
Current Share Price	€1.36
52 Week High	€1.44
52 Week Low	€0.92
Beta	0.053
11 Month Change	9.84%
3 Month Change	5.75%
1 Year Change	9.99%
33 Year Change	-51.44%
5 Year Change	n/a
Change since IPO	-80.83%

Recent updates

Shareholder Returns

	0RAG	GB Biotechs	GB Market
7D	0%	0.3%	2.2%
1Y	10.0%	-18.3%	8.0%

Return vs Industry: 0RAG exceeded the UK Biotechs industry which returned -18.3% over the past year.

Return vs Market: 0RAG exceeded the UK Market which returned 8% over the past year.

Price Volatility

Is 0RAG's price volatile compared to industry and market?
0RAG volatility
0RAG Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0RAG's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0RAG's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2005	61	Cyrille Tupin	abionyx.com

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019.

ABIONYX Pharma SA Fundamentals Summary

How do ABIONYX Pharma's earnings and revenue compare to its market cap?
0RAG fundamental statistics
Market cap	€42.31m
Earnings (TTM)	-€3.36m
Revenue (TTM)	€4.86m

8.7x

P/S Ratio

-12.6x

P/E Ratio

Is 0RAG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RAG income statement (TTM)
Revenue	€4.86m
Cost of Revenue	€3.92m
Gross Profit	€932.00k
Other Expenses	€4.29m
Earnings	-€3.36m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.097
Gross Margin	19.19%
Net Profit Margin	-69.15%
Debt/Equity Ratio	14.4%

How did 0RAG perform over the long term?

See historical performance and comparison

0RAG Stock Overview

Rewards

Risk Analysis

ABIONYX Pharma SA Competitors

AIM:AREC

UK£28.3m

AIM:TRX

UK£40.6m

AIM:AVCT

UK£179.3m

OFEX:PBX

UK£10.3m

Price History & Performance

Recent News & Updates

ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting Kidney Week

First half 2024 earnings released

ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

ABIONYX Pharma SA, Annual General Meeting, Jun 27, 2024

ABIONYX Pharma SA to Report Q2, 2024 Results on Aug 22, 2024

Insufficient new directors

Recent updates

ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting Kidney Week

First half 2024 earnings released

ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

ABIONYX Pharma SA, Annual General Meeting, Jun 27, 2024

ABIONYX Pharma SA to Report Q2, 2024 Results on Aug 22, 2024

Insufficient new directors

Insufficient new directors

New minor risk - Revenue size

Full year 2023 earnings released

ABIONYX Pharma SA to Report Q2, 2024 Results on Sep 26, 2024

Insufficient new directors

ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring’S Human-Plasma-Derived Apoa-I, CSL112

ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D

ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023

ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I

Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology (Asn) 2023 Annual Meeting "Kidney Week"

New minor risk - Share price stability

ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"

First half 2023 earnings released

New minor risk - Shareholder dilution

ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess

New major risk - Revenue and earnings growth

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma SA, Annual General Meeting, Jun 28, 2023

ABIONYX Pharma SA to Report Q2, 2023 Results on Aug 17, 2023

ABIONYX Pharma Announces Successful Manufacturing of the First Batch of CER-001 with Recombinant Human ApoA-I Using aNew Innovative and Robust Industrial Bioprocess

Full year 2022 earnings released

ABIONYX Pharma Reports Positive Results from Phase 2A Pilot Clinical Trial

ABIONYX Pharma SA to Report Fiscal Year 2022 Results on Apr 27, 2023

Insufficient new directors

Insufficient new directors

Insufficient new directors

ABIONYX Pharma SA Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury

Insufficient new directors

First half 2022 earnings released

ABIONYX Pharma Reports Positive Interim Results from Phase 2A Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients At High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease

ABIONYX Pharma SA to Report First Half, 2022 Results on Sep 29, 2022

ABIONYX Pharma Announces That the French Drug Safety Agency Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease

ABIONYX Announces First Patient Enrolled in Phase 2a Clinical Study With CER-001, the Bio-HDL for the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Investor sentiment improved over the past week

ABIONYX Announces Positive Clinical Results From CER-001 in an Ultrarare Kidney Disease Published in the Annals of Internal Medicine

ABIONYX Pharma SA to Report First Half, 2021 Results on Sep 09, 2021

ABIONYX Pharma SA Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Announces Publication of Pre-Clinical Data in the Journal Metabolism Demonstrating CER-001 Improves Lipid Profile and Kidney Function for an Ultra-Rare Kidney Disease

ABIONYX Pharma Announces the Observation of Positive Therapeutic Signals in Temporary Authorizations for Use (ATUn) in France and Italy for an Ultra-Rare Kidney Disease

ABIONYX Pharma SA announced that it expects to receive €1.859997 million in funding from Domundi SC and other investors

Shareholder Returns

Price Volatility

About the Company

ABIONYX Pharma SA Fundamentals Summary

8.7x

-12.6x

Earnings & Revenue